Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Value and Influencing Factors of Tegoprazan Test for GERD
ChiCTR2200065994Phase 4Not yet recruiting
- Sponsor
- Third People's Hospital of Chengdu
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tegoprazan in gastroesophageal reflux disease (GERD), sponsored by Third People's Hospital of Chengdu. Primary endpoints: Sensitivity of the Tegoprazan test for diagnosing GERD and Specificity of the Tegoprazan test for diagnosing GERD. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ChiCTR2200065994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065994.